Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $74.1 million.

  • TScan Therapeutics' Non-Current Assets rose 15.96% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.8 million, marking a year-over-year increase of 146.85%. This contributed to the annual value of $78.4 million for FY2024, which is 62.12% up from last year.
  • Latest data reveals that TScan Therapeutics reported Non-Current Assets of $74.1 million as of Q3 2025, which was up 15.96% from $77.4 million recorded in Q2 2025.
  • TScan Therapeutics' Non-Current Assets' 5-year high stood at $78.4 million during Q4 2024, with a 5-year trough of $17.9 million in Q3 2021.
  • Its 5-year average for Non-Current Assets is $57.6 million, with a median of $74.0 million in 2024.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 23387.08% in 2022, then rose by 15.96% in 2025.
  • Over the past 5 years, TScan Therapeutics' Non-Current Assets (Quarter) stood at $22.5 million in 2021, then skyrocketed by 233.87% to $75.0 million in 2022, then rose by 3.93% to $77.9 million in 2023, then grew by 0.62% to $78.4 million in 2024, then dropped by 5.53% to $74.1 million in 2025.
  • Its Non-Current Assets was $74.1 million in Q3 2025, compared to $77.4 million in Q2 2025 and $77.9 million in Q1 2025.